AstraZeneca (AZN-0.67%) hopes to soon close its planned acquisition of Alexion Pharmaceuticals . The only hurdle left to jump is obtaining approval from United Kingdom regulators.

Anglo-Swedish drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest agreement struck by a pharmaceutical company since the start of the Covid ...

AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals for $39 billion, a deal aimed at boosting AstraZeneca's immunology and rare-disease research, combining the companies ...

Just as any takeover target would, Alexion asked AstraZeneca to increase its buyout offer several times before the two shook hands on the $39 billion deal unveiled in December.

UK-based AstraZeneca said it wrapped up its $39 billion acquisition of Alexion on Wednesday, a week after clearing its final hurdle with a green light from UK regulators.

Coronavirus vaccine maker AstraZeneca has been given the all-clear by the UK competition watchdog to go ahead with its 39 billion US dollar (£28.2 billion) megadeal to buy US drug company Alexion ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

Under the terms of the deal, AstraZeneca will pay $60 in cash and 2.1243 of its American depositary receipts for each of Alexion’s shares. That amounts to $175 a share, a nearly 45 percent ...

AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN). The only hurdle left to jump is obtaining approval from United Kingdom regulators.

Drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest agreement struck by a pharmaceutical company since the start of the Covid-19 pandemic.